DK1100488T3 - Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv - Google Patents

Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv

Info

Publication number
DK1100488T3
DK1100488T3 DK98942645T DK98942645T DK1100488T3 DK 1100488 T3 DK1100488 T3 DK 1100488T3 DK 98942645 T DK98942645 T DK 98942645T DK 98942645 T DK98942645 T DK 98942645T DK 1100488 T3 DK1100488 T3 DK 1100488T3
Authority
DK
Denmark
Prior art keywords
bone
treatment
creatine compounds
tissues
cartilage cells
Prior art date
Application number
DK98942645T
Other languages
Danish (da)
English (en)
Inventor
Theo Wallimann
Isabel Gerber
Original Assignee
Synthes Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthes Ag filed Critical Synthes Ag
Application granted granted Critical
Publication of DK1100488T3 publication Critical patent/DK1100488T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3821—Bone-forming cells, e.g. osteoblasts, osteocytes, osteoprogenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0015—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3817—Cartilage-forming cells, e.g. pre-chondrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3847—Bones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body
    • A61L27/3843—Connective tissue
    • A61L27/3852—Cartilage, e.g. meniscus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
DK98942645T 1998-07-28 1998-07-28 Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv DK1100488T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/004713 WO2000006150A1 (fr) 1998-07-28 1998-07-28 Utilisation de composes a base de creatine pour traiter les cellules et les tissus osseux et cartilagineux

Publications (1)

Publication Number Publication Date
DK1100488T3 true DK1100488T3 (da) 2003-08-11

Family

ID=8167021

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98942645T DK1100488T3 (da) 1998-07-28 1998-07-28 Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv

Country Status (11)

Country Link
US (2) US20020039567A1 (fr)
EP (1) EP1100488B1 (fr)
JP (1) JP4778143B2 (fr)
AT (1) ATE238049T1 (fr)
CA (1) CA2338712C (fr)
DE (1) DE69813908T2 (fr)
DK (1) DK1100488T3 (fr)
ES (1) ES2198067T3 (fr)
HK (1) HK1037910A1 (fr)
PT (1) PT1100488E (fr)
WO (1) WO2000006150A1 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242491B1 (en) * 1999-06-25 2001-06-05 Rima Kaddurah-Daouk Use of creatine or creatine compounds for skin preservation
US7005274B1 (en) 1999-09-15 2006-02-28 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
EP1242577B1 (fr) * 1999-12-28 2008-04-16 The Regents Of The University Of Michigan Methode de formation ex vivo d'os de mammifere et utilisations dudit os
US6811776B2 (en) 2000-12-27 2004-11-02 The Regents Of The University Of Michigan Process for ex vivo formation of mammalian bone and uses thereof
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
ES2522890T3 (es) 2000-12-06 2014-11-19 Anthrogenesis Corporation Método para recolectar células troncales placentarias
US7575743B2 (en) * 2001-01-30 2009-08-18 Orthogene, Inc. Compositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
EP2336299A1 (fr) * 2001-02-14 2011-06-22 Anthrogenesis Corporation Placenta post-gravidique de mammifere, son utilisation et cellules souches placentaires correspondantes
ES2522526T3 (es) * 2001-02-14 2014-11-14 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células troncales placentarias de la misma
KR20050075507A (ko) * 2004-01-15 2005-07-21 재단법인서울대학교산학협력재단 시클로크레아틴을 포함하는 골대사성 질환의 예방 및치료를 위한 조성물
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US7736669B2 (en) * 2004-11-30 2010-06-15 University Of Washington Porous structures, and methods of use
JP4914594B2 (ja) * 2005-09-29 2012-04-11 ユニテックフーズ株式会社 関節痛改善用食品組成物
WO2007047468A2 (fr) 2005-10-13 2007-04-26 Anthrogenesis Corporation Immunomodulation realisee avec des cellules souches placentaires
NZ571113A (en) 2005-11-17 2012-02-24 Biomimetic Therapeutics Inc Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
US8455250B2 (en) 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
KR20190104428A (ko) 2005-12-29 2019-09-09 안트로제네시스 코포레이션 태반 줄기 세포 집단
AU2007210068A1 (en) 2006-01-26 2007-08-09 The Board Of Regents, The University Of Texas System Process and apparatus for imaging
CA2641860C (fr) 2006-02-09 2015-07-14 Biomimetic Therapeutics, Inc. Compositions et methodes pour le traitement d'os
US20090247647A1 (en) * 2006-03-28 2009-10-01 Brian Genge Method of Stimulating Proteoglycan Synthesis in Cells
EP2035552A2 (fr) * 2006-06-09 2009-03-18 Anthrogenesis Corporation Niche placentaire et son utilisation pour cultiver des cellules souches
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
CA2656278C (fr) 2006-06-30 2016-02-09 Biomimetic Therapeutics, Inc. Compositions et procedes destines au traitement de lesions de la coiffe des rotateurs
WO2008073628A2 (fr) 2006-11-03 2008-06-19 Biomimetic Therapeutics, Inc. Compositions et procédés pour procédures arthrodétiques
DE102007004781A1 (de) 2007-01-31 2008-08-07 Alzchem Trostberg Gmbh Verwendung von Guanidinoessigsäure(-Salzen) zur Herstellung eines gesundheitsfördernden Mittels
MX349225B (es) 2007-02-12 2017-07-19 Anthrogenesis Corp Uso de celulas madre placentarias para preparar medicamentos utiles en el tratamiento de padecimientos inflamatorios.
JP4818177B2 (ja) * 2007-03-27 2011-11-16 ユニテックフーズ株式会社 高齢者向け骨・筋肉増強促進組成物
JP5157007B2 (ja) * 2007-05-11 2013-03-06 ビーエイチエヌ株式会社 骨強化剤
TWM322542U (en) * 2007-05-23 2007-11-21 Universal Scient Ind Co Ltd Testing machine
US20090105196A1 (en) * 2007-06-22 2009-04-23 Belinda Tsao Nivaggioli Use of creatine compounds to treat dermatitis
DE102007030495A1 (de) 2007-06-30 2009-01-15 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der Gedächtnisleistung, der Merkfähigkeit, des Langzeitgedächtnisses und zur Vorbeugung geistiger Ermüdungszustände
KR20210022148A (ko) 2007-09-28 2021-03-02 안트로제네시스 코포레이션 인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
DE102007053369A1 (de) 2007-11-09 2009-07-02 Alzchem Trostberg Gmbh Verwendung einer eine Kreatin-Komponente enthaltende Zusammensetzung zur Verbesserung der männlichen Fruchtbarkeit
DE102007062288A1 (de) 2007-12-21 2009-06-25 Alzchem Trostberg Gmbh Kreatin-Zubereitung und Verfahren zu deren Herstellung
AU2009212151C1 (en) 2008-02-07 2015-09-17 Biomimetic Therapeutics, Llc Compositions and methods for distraction osteogenesis
MX2011001991A (es) * 2008-08-20 2011-03-29 Anthrogenesis Corp Tratamiento de la apoplejia utilizando celulas placentarias aisladas.
EP3539380A3 (fr) 2008-08-20 2019-12-18 Celularity, Inc. Composition améliorée de cellules et son procédé de fabrication
WO2010021756A1 (fr) 2008-08-22 2010-02-25 Anthrogenesis Corporation Méthodes et compositions pour le traitement de déficits osseux au moyen de populations de cellules placentaires
NZ602861A (en) 2008-09-09 2014-03-28 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
US7874536B2 (en) * 2008-09-26 2011-01-25 Groover David O Angle ceiling hanger or bracket
DK2367932T3 (da) * 2008-11-19 2019-09-23 Celularity Inc Amnion-afledte adhærente celler
ES2731340T3 (es) * 2008-11-21 2019-11-15 Celularity Inc Tratamiento de enfermedades, trastornos o afecciones pulmonares utilizando células placentarias
ES2646750T3 (es) * 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
EP2538791B1 (fr) 2010-02-22 2015-04-08 BioMimetic Therapeutics, LLC Compositions de facteur de croissance dérivé des plaquettes et procédés pour le traitement de tendinopathies
HUE029144T2 (hu) 2010-04-07 2017-02-28 Anthrogenesis Corp Angiogenezis méhlepény õssejtek használatával
CA2795401A1 (fr) 2010-04-08 2011-10-13 Anthrogenesis Corporation Traitement de la sarcoidose au moyen de cellules souches du sang placentaire
WO2011154413A1 (fr) * 2010-06-07 2011-12-15 Fritz-Lipmann-Insitut E. V. Leibniz-Institut Für Altersforschung Agent contre l'ostéoporose induite par les glucocorticoïdes
EP2593542B1 (fr) 2010-07-13 2018-01-03 Anthrogenesis Corporation Procédés de génération de cellules tueuses naturelles
JP5756614B2 (ja) * 2010-11-02 2015-07-29 花王株式会社 オートインデューサー−２阻害剤、並びに齲蝕病の予防及び／又は治療剤
WO2012092485A1 (fr) 2010-12-31 2012-07-05 Anthrogenesis Corporation Amélioration de l'efficacité de cellules souches placentaires sous l'effet de molécules d'arn modulateur
US9157908B2 (en) 2011-04-22 2015-10-13 University Of Washington Through Its Center For Commercialization Chitosan-alginate scaffold cell culture system and related methods
EP3443968A1 (fr) 2011-06-01 2019-02-20 Celularity, Inc. Traitement de la douleur à l'aide de cellules souches placentaires
WO2013055476A1 (fr) 2011-09-09 2013-04-18 Anthrogenesis Corporation Traitement de la sclérose latérale amyotrophique au moyen de cellules souches placentaires
CN102897735B (zh) * 2012-11-12 2014-07-16 中国科学院上海硅酸盐研究所 微波辅助制备羟基磷灰石空心球
CN105142651A (zh) 2013-02-05 2015-12-09 人类起源公司 来自胎盘的自然杀伤细胞
US11318166B2 (en) 2014-06-04 2022-05-03 Cedars-Sinai Medical Center Method for non surgical repair of vertebral compression fractures
EP3415527A1 (fr) 2017-06-14 2018-12-19 Technische Universität Dresden Utilisation du domaine extracellulaire du récepteur de transfert 2 destiné au diagnostic et au traitement des pathologies sclérosantes primaires et secondaires
CN112236166A (zh) * 2018-06-13 2021-01-15 科马布有限公司 用于治疗骨疾病的转铁蛋白受体-2的拮抗剂和激动剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4647453A (en) * 1984-10-18 1987-03-03 Peritain, Ltd. Treatment for tissue degenerative inflammatory disease
US4772591A (en) * 1985-09-25 1988-09-20 Peritain, Ltd. Method for accelerated wound healing
US5693615A (en) * 1991-06-05 1997-12-02 The Procter & Gamble Company Therapeutic compositions for osteoinduction
JPH05238929A (ja) * 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
JPH07157439A (ja) * 1993-12-07 1995-06-20 Eisai Co Ltd 骨内部埋め込み用製剤
CA2235350C (fr) * 1994-11-08 2009-01-06 Avicena Group, Inc. Utilisation de la creatine ou d'analogues de la creatine pour le traitement de maladies du systeme nerveux
EP0811383B1 (fr) * 1995-02-20 2007-05-30 Yukio Kato Remedes contre la polyarthrite rhumatoide et les maladies articulaires inflammatoires
AU723740B2 (en) * 1995-06-06 2000-09-07 Howmedica Inc. Biocompatible hydroxyapatite formulations and uses therefor
DE19529223A1 (de) * 1995-08-09 1997-02-13 Boehringer Mannheim Gmbh Verwendung von Plasminogenaktivatoren zum lokalen Knochenaufbau
CA2231632C (fr) * 1995-10-11 2004-01-20 Avicena Group, Inc. Utilisation d'analogues de creatine pour le traitement de troubles du metabolisme du glucose
US5998457A (en) * 1995-10-26 1999-12-07 Avicena Group, Inc. Creatine analogues for treatment of obesity
EP0915967A1 (fr) * 1996-05-28 1999-05-19 The Board Of Regents Of The University Of Michigan Reconstitution de tissus buccaux
US5716926A (en) * 1996-07-26 1998-02-10 Paxton K. Beale Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US5756469A (en) * 1996-07-26 1998-05-26 Beale; Paxton K. Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
DE69729004T2 (de) * 1996-10-10 2005-04-07 The General Hospital Corp., Boston Photodynamische therapie zur behandlung von osteosrthritis
US5888553A (en) * 1997-04-08 1999-03-30 Infinity, Inc. Non-steroidal anabolic composition
US5886040A (en) * 1997-06-17 1999-03-23 Amt Labs, Inc. Creatine pyruvate salt with enhanced palatability
EP0891719A1 (fr) * 1997-07-14 1999-01-20 N.V. Nutricia Composition dietique contenant de la methionine

Also Published As

Publication number Publication date
US20050085543A1 (en) 2005-04-21
ATE238049T1 (de) 2003-05-15
US20020039567A1 (en) 2002-04-04
WO2000006150A1 (fr) 2000-02-10
JP2002521440A (ja) 2002-07-16
PT1100488E (pt) 2003-09-30
ES2198067T3 (es) 2004-01-16
DE69813908T2 (de) 2004-02-05
EP1100488B1 (fr) 2003-04-23
DE69813908D1 (de) 2003-05-28
JP4778143B2 (ja) 2011-09-21
CA2338712A1 (fr) 2000-02-10
EP1100488A1 (fr) 2001-05-23
HK1037910A1 (en) 2002-02-22
CA2338712C (fr) 2012-10-09

Similar Documents

Publication Publication Date Title
DK1100488T3 (da) Anvendelse af creatinforbindelser til behandling af knogle- eller bruskceller og -væv
Granströ et al. Bone-anchored reconstruction of the irradiated head and neck cancer patient
Nishimura et al. Auricular prostheses and osseointegrated implants: UCLA experience
Spiessl New concepts in maxillofacial bone surgery
Holgers et al. Soft tissue reactions around percutaneous implants: a clinical study on skin-penetrating titanium implants used for bone-anchored auricular prostheses.
Nyström et al. Bone grafts and Brånemark implants in the treatment of the severely resorbed maxilla: a 2-year longitudinal study.
Wilson Jr et al. Total hip replacement with fixation by acrylic cement: a preliminary study of 100 consecutive McKee-Farrar prosthetic replacements
Granström Craniofacial osseointegration
Roumanas et al. Craniofacial Defects and Osseointegrated Implants: Six-Year Follow-up Report on the Success Rates of Craniofacial Implants at UCLA.
SNYDER et al. Mandibulo-facial restoration with live osteocutaneous flaps
Tolman et al. Extraoral application of osseointegrated implants
Ueda et al. Effect of hyperbaric oxygen therapy on osseointegration of titanium implants in irradiated bone: a preliminary report.
ES2163442T3 (es) Utilizacion de particulas de una sal de calcio biocompatible y bio-reabsorbible como ingrediente activo en la preparacion de un medicamento destinado para el tratamiento local de enfermedades desmineralizantes de los huesos.
Jacobsson et al. Tissue-integrated implants in children
Peckitt Stereoscopic lithography: customized titanium implants in orofacial reconstruction
Zhao et al. Clinical evaluation of three total ear reconstruction methods
Marker et al. Osseointegrated implants for prosthetic rehabilitation after treatment of cancer of the oral cavity
Cohen et al. Mandibular reconstruction
Cummings Experimental observations of canine mandibular regeneration following segmental removal, freezing, and reimplantation
RU2359621C1 (ru) Способ хирургического лечения рака гортани
El-Sheikh et al. The split rib bundle graft in mandibular reconstruction
Schlegel et al. Clinical Trial of Modified Ankylos Implants for Extraoral Use in Cranio-and Maxillofacial Surgery.
Huang et al. Chin projection creation in patients with facial and cervical burn scar contracture
Marciani et al. Cancellous-marrow bone grafts in irradiated tissue
RU2250789C2 (ru) Способ лечения повреждений костей при замедленной консолидации